Investor Relations

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.

CR-000172

News Releases

News Releases

The information set forth in each press release posted on this page was factually accurate on the date it was issued. While these press releases remain on the Company's website, the Company assumes no duty to update the information to reflect subsequent developments. Consequently, readers of the press releases should not rely upon the information as current or accurate after their issuance dates.

Date Title
06/07/21
Charles River Laboratories Announces Long-Term Solar Contract for North American Operations
05/28/21
Charles River Laboratories to Participate in June Investor Conferences
05/26/21
Charles River Laboratories to Host Virtual Investor Day
05/17/21
Charles River Laboratories to Acquire Vigene Biosciences to Enhance Gene Therapy Capabilities
05/04/21
Charles River Laboratories Announces First-Quarter 2021 Results
04/13/21
Charles River Laboratories Schedules First-Quarter 2021 Earnings Release and Conference Call
04/06/21
Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities
03/31/21
Charles River Laboratories Acquires Retrogenix
03/29/21
Charles River Laboratories Completes the Acquisition of Cognate BioServices
03/23/21
Charles River Laboratories Announces Closing of Senior Notes Offering
03/09/21
Charles River Laboratories Prices $1 Billion of Senior Notes
03/08/21
Charles River Laboratories Announces Planned Offering of $1 Billion of Senior Notes
03/08/21
Charles River Laboratories to Present at Barclays Global Healthcare Conference
02/25/21
Charles River Laboratories Announces Strategic Partnership with Kibur Medical to Advance Preclinical Oncology Studies
02/17/21
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2020 Results and Provides 2021 Guidance
02/17/21
Charles River Laboratories to Acquire Cognate BioServices to Create a Premier Scientific Partner for Cell and Gene Therapy Development
01/28/21
Charles River Announces Strategic Partnership with Cypre, Expanding 3D In Vitro Services for Cancer Immunotherapy and Targeted Therapy Drug Screening
01/20/21
Charles River Laboratories Schedules Fourth-Quarter 2020 Earnings and 2021 Guidance Release and Conference Call
01/14/21
Charles River Partners with JADE Biomedical to Expand Biologics Capabilities
01/11/21
Charles River Laboratories to Present at J.P. Morgan Healthcare Conference
01/04/21
Charles River Laboratories Acquires Distributed Bio

Featured Report

2020 Annual Report (PDF)

Charles River Corporate Citizenship Report
View PDF
Print PDF